It has been nearly 9years since the FDA (Food and Drug Administration) approved the first
anti-angiogenic drug (bevacizumab) for treatment of metastatic colorectal cancer. Other …

Standard-of-care management of renal cell carcinoma (RCC) indisputably relies on surgery
for low-risk localized tumours and systemic treatment for poor-prognosis metastatic disease …

Purpose: Vascular endothelial growth factor targeted therapy is a standard of care in
patients with metastatic renal cell carcinoma. The role of cytoreductive nephrectomy in the …

The most common renal cancer is renal cell carcinoma (RCC), which arises from the renal
parenchyma. The global incidence of RCC has increased over the past two decades by 2 …

Molecular and cellular mechanisms underlying resistance/low responsiveness to
antiangiogenic compounds are under extensive investigations. Both populations of tumor …

The molecular mechanisms responsible for the failure of antiangiogenic therapies and how
tumors adapt to these therapies are unclear. Here, we applied transcriptomic, proteomic …

BACKGROUND: Targeted molecular therapies (TMTs) previously have demonstrated
oncologic activity in renal cell carcinoma (RCC) by reducing the size of primary tumors and …

Background Previous studies have shown a modest impact of tyrosine kinase inhibitors on
primary renal tumors. Those studies were mostly retrospective or heterogeneous in their …

Purpose Ongoing angiogenesis renders the tumor endothelium unresponsive to
inflammatory cytokines and interferes with adhesion of leukocytes, resulting in escape from …

Purpose: We assessed the activity of neoadjuvant sunitinib on primary renal tumors in
patients with advanced renal cell carcinoma as well as the feasibility and safety of …